Welcome to our dedicated page for Structure Therapeutics ADR news (Ticker: GPCR), a resource for investors and traders seeking the latest updates and insights on Structure Therapeutics ADR stock.
Structure Therapeutics Inc. develops oral small-molecule therapeutics for chronic metabolic diseases, with a focus on obesity. The clinical-stage global biopharmaceutical company uses a structure-based drug discovery platform and GPCR-targeted pipeline to advance wholly owned compounds, including aleniglipron, an oral nonpeptide GLP-1 receptor agonist, and ACCG-2671, an oral amylin receptor agonist.
Recurring company updates include clinical data from the ACCESS aleniglipron program, obesity and weight-management research presentations, financial results, research-and-development funding, ADS and warrant financings, and leadership or governance changes. The company’s American depositary shares trade under GPCR, with each ADS representing three ordinary shares.
Structure Therapeutics (NASDAQ: GPCR), a clinical-stage biopharmaceutical company focused on developing oral small molecule therapeutics for metabolic diseases, has announced its participation in three upcoming healthcare investor conferences.
The company will attend the Guggenheim SMID Cap Biotech Conference on February 5 in New York, featuring a fireside chat at 10:30 a.m. ET, the Leerink Global Healthcare Conference on March 10 in Miami with a fireside chat at 1:00 p.m. ET, and the Jefferies Biotech on the Bay Summit on March 11 in Miami for one-on-one meetings.
Webcasts of the fireside chats will be available on the company's investor relations website, with replays accessible for 90 days following the events.
Structure Therapeutics (NASDAQ: GPCR) has announced ACCG-2671 as its lead oral small molecule amylin receptor agonist for obesity treatment. The drug, designed as an oral Dual Amylin and Calcitonin Receptor Agonist (DACRA), is expected to enter Phase 1 clinical trials by year-end 2025.
Preclinical studies showed ACCG-2671 demonstrates potent target engagement, robust weight loss, and favorable safety profile supporting once-daily dosing. The company positions it as the most advanced oral small molecule amylin-based drug candidate, complementing their GLP-1 oral molecule GSBR-1290, with both intended for use as monotherapies and in fixed-dose combinations.
The drug showed cagrilintide-like efficacy in preclinical data with an oral small molecule profile, targeting amylin, a hormone that regulates glycemia and energy balance.
Structure Therapeutics (NASDAQ: GPCR), a clinical-stage biopharmaceutical company focused on developing oral small molecule therapeutics for metabolic and cardiopulmonary diseases, has announced its participation in the Jefferies London Healthcare Conference. The event will take place from November 19-21, 2024, in London, UK.
The company's management will deliver a presentation and participate in a fireside chat on Wednesday, November 20 at 8:00 a.m. GMT, while also hosting one-on-one meetings. A live webcast will be available on the company's website, with a replay accessible for 90 days following the event.
Structure Therapeutics (NASDAQ: GPCR) reported Q3 2024 financial results and recent milestones. The company has initiated Phase 2b ACCESS study of GSBR-1290 for obesity treatment, with topline data expected in Q4 2025. The company maintains a strong financial position with $915.3 million in cash and investments, expected to fund operations through 2027. Q3 2024 financial results show R&D expenses of $32.6 million (up from $17.5M in Q3 2023), G&A expenses of $13.2 million (up from $8.6M), and a net loss of $34.0 million. The company plans to select an oral small molecule amylin receptor agonist development candidate by end of 2024.
Structure Therapeutics has initiated dosing in its Phase 2b ACCESS clinical study for GSBR-1290, an oral small molecule GLP-1 receptor agonist for obesity treatment. The study will evaluate multiple doses up to 120 mg over 36 weeks in approximately 220 participants. Additionally, the company announced the Phase 2 ACCESS II study, which will test higher doses (180 and 240 mg) in about 82 participants. Both studies employ a "low and slow" titration approach, with topline data expected in Q4 2025. GSBR-1290 has shown competitive weight loss results and favorable safety in previous studies with once-daily dosing.
Structure Therapeutics (NASDAQ: GPCR) has announced multiple poster presentations at ObesityWeek® 2024, scheduled for November 3-6, 2024 in San Antonio, TX. The company will present three posters focusing on obesity treatment innovations:
1. A presentation on novel oral small molecule dual amylin and calcitonin receptor agonists for obesity treatment
2. Research on drug design principles and PK/PD of GSBR-1290, a small molecule GLP-1RA
3. Clinical results showing significant weight changes at 12 weeks with GSBR-1290
All presentations will take place in Exhibit Hall 4, with specific sessions scheduled for November 3-4.
Structure Therapeutics Inc. (NASDAQ: GPCR) has announced key leadership changes to drive its next phase of development. Blai Coll, M.D., Ph.D., has been promoted to Chief Medical Officer, replacing Mark Bach, M.D., Ph.D., effective September 18, 2024. Dr. Coll has been leading the GSBR-1290 program, an oral small molecule GLP-1 agonist for obesity, set to enter Phase 2b clinical trials in Q4 2024.
Additionally, Ashley Hall, J.D., has been appointed as Chief Development Officer, a new position overseeing clinical development operations, project management, regulatory affairs, and quality assurance. These appointments aim to strengthen the company's position as it advances its clinical programs, including the development of an oral amylin compound.
Structure Therapeutics Inc. (NASDAQ: GPCR) has appointed Angus C. Russell to its board of directors. Mr. Russell, former CEO of Shire plc, brings over 30 years of experience in the global biopharmaceutical industry. This appointment comes as Structure prepares to advance its oral small molecule GLP-1 agonist, GSBR-1290, into late-stage clinical development for obesity. CEO Raymond Stevens highlighted Russell's expertise in strategy, finance, operations, and commercialization as valuable assets for the company's growth. Russell expressed enthusiasm for Structure's potential in the obesity market, particularly with GSBR-1290 and its pipeline of oral small molecule therapeutics.
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company focusing on novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, has announced its participation in two upcoming investor conferences in September 2024:
1. Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on Thursday, September 5 at 10:00 a.m. EDT
2. Cantor Fitzgerald Global Healthcare Conference 2024: Fireside chat on Thursday, September 19 at 9:10 a.m. EDT
Live and archived webcasts of both fireside chats will be available on the company's website, with replays accessible for 90 days after the events.
Structure Therapeutics (NASDAQ: GPCR) reported Q2 2024 financial results and recent highlights. Key points include:
1. GSBR-1290 Phase 2b obesity study on track for Q4 2024 initiation.
2. Oral small molecule amylin receptor agonist development candidate expected in Q4 2024.
3. Strong financial position with $927.1 million cash balance, funding operations through at least 2027.
4. Q2 2024 R&D expenses increased to $22.1 million from $19.4 million in Q2 2023.
5. Q2 2024 G&A expenses rose to $11.3 million from $6.6 million in Q2 2023.
6. Net loss for Q2 2024 was $26.0 million, compared to $23.3 million in Q2 2023.
7. GSBR-1290 Phase 2a results showed 6.2% placebo-adjusted mean weight loss at 12 weeks.